Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases.

Durozard P, Rico A, Boutiere C, Maarouf A, Lacroix R, Cointe S, Fritz S, Brunet C, Pelletier J, Marignier R, Audoin B.

Ann Neurol. 2019 Nov 14. doi: 10.1002/ana.25648. [Epub ahead of print]

PMID:
31725931
2.

Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes.

Duignan S, Wright S, Rossor T, Cazabon J, Gilmour K, Ciccarelli O, Wassmer E, Lim M, Hemingway C, Hacohen Y.

Dev Med Child Neurol. 2018 Sep;60(9):958-962. doi: 10.1111/dmcn.13703. Epub 2018 Feb 22.

3.

Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease.

Mariano R, Messina S, Kumar K, Kuker W, Leite MI, Palace J.

JAMA Netw Open. 2019 Oct 2;2(10):e1912732. doi: 10.1001/jamanetworkopen.2019.12732.

4.

Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.

Bouzar M, Daoudi S, Hattab S, Bouzar AA, Deiva K, Wildemann B, Reindl M, Jarius S.

J Neurol Sci. 2017 Oct 15;381:240-244. doi: 10.1016/j.jns.2017.08.3254. Epub 2017 Aug 31.

PMID:
28991690
5.

Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders.

López-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, Jitprapaikulsan J, Kothapalli N, Tillema JM, Chen J, Weinshenker B, Wingerchuk D, Sagen J, Gadoth A, Lennon VA, Keegan BM, Lucchinetti C, Pittock SJ.

JAMA Neurol. 2018 Nov 1;75(11):1355-1363. doi: 10.1001/jamaneurol.2018.1814.

6.

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.

Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, Küker W, Chandratre S, Vincent A, Palace J.

JAMA Neurol. 2014 Mar;71(3):276-83. doi: 10.1001/jamaneurol.2013.5857.

PMID:
24425068
7.

Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease.

Hamid SHM, Whittam D, Saviour M, Alorainy A, Mutch K, Linaker S, Solomon T, Bhojak M, Woodhall M, Waters P, Appleton R, Duddy M, Jacob A.

JAMA Neurol. 2018 Jan 1;75(1):65-71. doi: 10.1001/jamaneurol.2017.3196.

8.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.

Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, Bellmann-Strobl J, Jarius S, Wildemann B, Reindl M, Waldman A, Soelberg K, Asgari N, Ringelstein M, Aktas O, Gross N, Buttmann M, Ach T, Ruprecht K, Paul F, Brandt AU; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Nov 1;13(1):282.

9.

Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.

Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson AP, Vucic S, Gorman MP, Benson LA, Alper G, Riney CJ, Barnett M, Parratt JD, Hardy TA, Leventer RJ, Merheb V, Nosadini M, Fung VS, Brilot F, Dale RC.

Mult Scler. 2016 Apr;22(4):470-82. doi: 10.1177/1352458515593406. Epub 2015 Jul 10.

PMID:
26163068
10.

Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis.

Martinez-Hernandez E, Sepulveda M, Rostásy K, Höftberger R, Graus F, Harvey RJ, Saiz A, Dalmau J.

JAMA Neurol. 2015 Feb;72(2):187-93. doi: 10.1001/jamaneurol.2014.3602.

11.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Sep 27;13(1):280.

12.

Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study.

Valentino P, Marnetto F, Granieri L, Capobianco M, Bertolotto A.

Neurol Neuroimmunol Neuroinflamm. 2016 Dec 15;4(2):e317. doi: 10.1212/NXI.0000000000000317. eCollection 2017 Mar.

13.

Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.

Chen JJ, Tobin WO, Majed M, Jitprapaikulsan J, Fryer JP, Leavitt JA, Flanagan EP, McKeon A, Pittock SJ.

JAMA Ophthalmol. 2018 Apr 1;136(4):419-422. doi: 10.1001/jamaophthalmol.2017.6757.

14.

Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China.

Zhao G, Chen Q, Huang Y, Li Z, Sun X, Lu P, Yan S, Wang M, Tian G.

J Neurol. 2018 Jan;265(1):33-40. doi: 10.1007/s00415-017-8651-4. Epub 2017 Nov 3.

PMID:
29101456
15.

The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis.

Liu H, Zhou H, Wang J, Sun M, Teng D, Song H, Xu Q, Wei S.

J Neurol Sci. 2019 Jan 15;396:225-231. doi: 10.1016/j.jns.2018.11.029. Epub 2018 Nov 28.

PMID:
30522039
16.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Trebst C, Ringelstein M, Aktas O, Winkelmann A, Buttmann M, Schwarz A, Zimmermann H, Brandt AU, Franciotta D, Capobianco M, Kuchling J, Haas J, Korporal-Kuhnke M, Lillevang ST, Fechner K, Schanda K, Paul F, Wildemann B, Reindl M; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Sep 26;13(1):279.

17.

Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.

Rostásy K, Mader S, Hennes EM, Schanda K, Gredler V, Guenther A, Blaschek A, Korenke C, Pritsch M, Pohl D, Maier O, Kuchukhidze G, Brunner-Krainz M, Berger T, Reindl M.

Mult Scler. 2013 Jul;19(8):1052-9. doi: 10.1177/1352458512470310. Epub 2012 Dec 20.

PMID:
23257621
18.

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.

Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, Palace J, Vincent A.

Neurology. 2012 Sep 18;79(12):1273-7. doi: 10.1212/WNL.0b013e31826aac4e. Epub 2012 Aug 22.

PMID:
22914827
19.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.

Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N, Hümmert MW, Trebst C, Pache F, Winkelmann A, Beume LA, Ringelstein M, Stich O, Aktas O, Korporal-Kuhnke M, Schwarz A, Lukas C, Haas J, Fechner K, Buttmann M, Bellmann-Strobl J, Zimmermann H, Brandt AU, Franciotta D, Schanda K, Paul F, Reindl M, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Nov 1;13(1):281.

20.

Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis.

Ramanathan S, Reddel SW, Henderson A, Parratt JD, Barnett M, Gatt PN, Merheb V, Kumaran RY, Pathmanandavel K, Sinmaz N, Ghadiri M, Yiannikas C, Vucic S, Stewart G, Bleasel AF, Booth D, Fung VS, Dale RC, Brilot F.

Neurol Neuroimmunol Neuroinflamm. 2014 Oct 29;1(4):e40. doi: 10.1212/NXI.0000000000000040. eCollection 2014 Dec.

Supplemental Content

Support Center